FDA Warning Letters to Compounders in 2026: What Practices Need to Know

The FDA has significantly increased its enforcement activity against compounding pharmacies in 2026, issuing warning letters at a pace that has put the entire industry on notice. For medical practices that source compounded medications, understanding what the FDA is finding — and what it means for your supply chain — is essential.

An FDA warning letter is an official communication from the FDA to a regulated entity notifying them of violations of FDA regulations. Warning letters are:

• Publicly posted on the FDA's website
• Serious: They represent the FDA's view that significant violations have occurred
• Action-requiring: The recipient must respond within a specified timeframe with a corrective action plan
• Consequential: Failure to respond or correct violations can lead to injunctions, seizures, or criminal prosecution

For compounding pharmacies, warning letters typically follow FDA inspections and identify specific violations of USP standards, CGMP requirements (for 503B facilities), or other applicable regulations.

The FDA's warning letters to compounders in 2026 have identified several recurring violation categories:

The most common violation in recent warning letters is the assignment of beyond-use dates (BUD dates) without adequate stability testing to support them. Compounders assigning 12-month BUD dates without the stability data to back them up are a primary enforcement target.

What this means for practices: Ask your supplier for the stability data supporting their BUD dates. If they cannot produce it, that is a red flag.

For sterile preparations, environmental monitoring (testing the cleanroom environment for microbial contamination) is required. Warning letters have cited inadequate monitoring programs, including insufficient sampling frequency and failure to investigate out-of-specification results.

The FDA has been increasingly aggressive in citing compounders for producing preparations that are "essentially a copy" of commercially available products without adequate justification. This is particularly relevant for GLP-1 compounds where branded products are available.

Several warning letters have cited compounders for using bulk drug substances that are not on the FDA's approved list for compounding, or for using substances from suppliers that are not registered with the FDA.

503B facilities are required to have robust quality systems including written procedures, batch records, and quality control testing. Warning letters have cited facilities with inadequate or poorly documented quality systems.

Compounded medications must meet specific labeling requirements. Warning letters have cited missing required information, incorrect BUD dates on labels, and other labeling deficiencies.

The FDA posts all warning letters on its website at fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters. You can search by company name.

Before ordering from any compounding supplier, check:

1. Has the company received any warning letters?
2. If so, when? And what was the violation?
3. Has the company responded and corrected the violations?

A warning letter is not necessarily disqualifying — if the company responded promptly and corrected the violations, it may still be a reliable supplier. But an unresolved warning letter or a pattern of violations is a serious red flag.

If your compounding supplier receives a warning letter, you need to:

1. Assess the violations: Are the violations related to the products you order? Do they affect product quality or safety?
2. Contact your supplier: Ask what corrective actions they are taking and what the timeline is.
3. Review your inventory: If you have product from lots that may be affected by the violations, consult with your supplier and consider whether to continue using it.
4. Document your response: Document your assessment and any actions you take. This demonstrates due diligence if you are ever questioned about your supply chain.
5. Consider alternatives: If the violations are serious or unresolved, consider sourcing from an alternative supplier while the issues are addressed.

Our pharmacy network has a clean regulatory record. We actively monitor FDA warning letters and enforcement actions affecting our supply partners, and we will proactively notify our clients if any issues arise.

Our founding team's legal background means we take compliance seriously — not as a marketing claim, but as a fundamental operating principle.

Contact us with compliance questions →

This content is for informational purposes only and does not constitute legal advice. FDA enforcement actions are publicly available at fda.gov.